预防人巨细胞病毒感染。
Preventing Infection by Human Cytomegalovirus.
机构信息
Department of Pediatrics, University of Pennsylvania, Vaxconsult, Doylestown, Pennsylvania, USA.
出版信息
J Infect Dis. 2020 Mar 5;221(Suppl 1):S123-S127. doi: 10.1093/infdis/jiz448.
Abstract
The way to a successful vaccine against human cytomegalovirus is hampered by the peculiar biology of this infection. However, some candidate vaccines have been shown to protect seronegative women and transplant recipients, and we should know soon whether they can prevent congenital infection.
摘要
针对人类巨细胞病毒的成功疫苗研制之路受到这种感染特殊生物学性质的阻碍。然而，一些候选疫苗已被证明可以保护血清阴性的妇女和移植受者，我们应该很快就会知道它们是否能预防先天性感染。
相似文献
1
Preventing Infection by Human Cytomegalovirus.预防人巨细胞病毒感染。
J Infect Dis. 2020 Mar 5;221(Suppl 1):S123-S127. doi: 10.1093/infdis/jiz448.
2
The Status of Vaccine Development Against the Human Cytomegalovirus.人类巨细胞病毒疫苗的研发现状。
J Infect Dis. 2020 Mar 5;221(Suppl 1):S113-S122. doi: 10.1093/infdis/jiz447.
3
Vaccination against the human cytomegalovirus.人巨细胞病毒疫苗接种。
Vaccine. 2019 Nov 28;37(50):7437-7442. doi: 10.1016/j.vaccine.2018.02.089. Epub 2018 Apr 3.
4
Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation.接种巨细胞病毒 gB-MF59 疫苗的血清阴性患者在移植后早期具有针对 gB 的中和抗体反应的证据。
EBioMedicine. 2019 Dec;50:45-54. doi: 10.1016/j.ebiom.2019.11.005. Epub 2019 Nov 15.
5
The history of vaccination against cytomegalovirus.抗巨细胞病毒疫苗接种史。
Med Microbiol Immunol. 2015 Jun;204(3):247-54. doi: 10.1007/s00430-015-0388-z. Epub 2015 Mar 20.
6
Scientific and Regulatory Considerations for Efficacy Studies of Cytomegalovirus Vaccines.巨细胞病毒疫苗疗效研究的科学和监管考虑因素。
J Infect Dis. 2020 Mar 5;221(Suppl 1):S103-S108. doi: 10.1093/infdis/jiz523.
7
Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.糖蛋白 B 疫苗接种可预防巨细胞病毒血症，而中和抗体对此并无影响。
Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):6273-6278. doi: 10.1073/pnas.1800224115. Epub 2018 Apr 23.
8
A Replication-Defective Human Cytomegalovirus Vaccine Elicits Humoral Immune Responses Analogous to Those with Natural Infection.复制缺陷型人巨细胞病毒疫苗可诱导类似于自然感染的体液免疫应答。
J Virol. 2019 Nov 13;93(23). doi: 10.1128/JVI.00747-19. Print 2019 Dec 1.
9
Criteria to define interruption of transmission of human cytomegalovirus from organ donor to recipient.界定器官捐献者向受者传播人巨细胞病毒中断的标准。
Rev Med Virol. 2018 Jan;28(1). doi: 10.1002/rmv.1958. Epub 2017 Nov 17.
10
Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity.多抗原性人巨细胞病毒 mRNA 疫苗可诱导强烈的体液和细胞介导免疫。
Vaccine. 2018 Mar 14;36(12):1689-1699. doi: 10.1016/j.vaccine.2018.01.029. Epub 2018 Feb 15.
引用本文的文献
1
A vaccine against cytomegalovirus: how close are we?一种抗巨细胞病毒的疫苗：我们距离它还有多远？
J Clin Invest. 2025 Jan 2;135(1):e182317. doi: 10.1172/JCI182317.
2
Spatial kinetics and immune control of murine cytomegalovirus infection in the salivary glands.唾液腺中鼠巨细胞病毒感染的空间动力学和免疫控制。
PLoS Comput Biol. 2024 Aug 16;20(8):e1011940. doi: 10.1371/journal.pcbi.1011940. eCollection 2024 Aug.
3
Re-Evaluating Human Cytomegalovirus Vaccine Design: Prediction of T Cell Epitopes.重新评估人巨细胞病毒疫苗设计：T细胞表位预测
Vaccines (Basel). 2023 Oct 24;11(11):1629. doi: 10.3390/vaccines11111629.
4
Updates in Cytomegalovirus Prevention and Treatment in Solid Organ Transplantation.实体器官移植中巨细胞病毒预防与治疗的进展
Infect Dis Clin North Am. 2023 Nov 20. doi: 10.1016/j.idc.2023.10.001.
5
Targeted Protein-Specific Multi-Epitope-Based Vaccine Designing against Human Cytomegalovirus by Using Immunoinformatics Approaches.利用免疫信息学方法针对人巨细胞病毒进行基于多表位的靶向蛋白质特异性疫苗设计。
Vaccines (Basel). 2023 Jan 17;11(2):203. doi: 10.3390/vaccines11020203.
6
An Attenuated Strain of Human Cytomegalovirus for the Establishment of a Subviral Particle Vaccine.用于制备亚病毒颗粒疫苗的人巨细胞病毒减毒株
Vaccines (Basel). 2022 Aug 16;10(8):1326. doi: 10.3390/vaccines10081326.
7
Lessons from Acquired Natural Immunity and Clinical Trials to Inform Next-Generation Human Cytomegalovirus Vaccine Development.从获得性天然免疫和临床试验中汲取经验教训，为下一代人巨细胞病毒疫苗的开发提供信息。
Annu Rev Virol. 2022 Sep 29;9(1):491-520. doi: 10.1146/annurev-virology-100220-010653. Epub 2022 Jun 15.
8
Modified vaccinia Ankara expressing EEHV1A glycoprotein B elicits humoral and cell-mediated immune responses in mice.改良安卡拉痘苗病毒表达 EHV-1A 糖蛋白 B 可在小鼠中引发体液和细胞介导的免疫应答。
PLoS One. 2022 Mar 21;17(3):e0265424. doi: 10.1371/journal.pone.0265424. eCollection 2022.
9
Understanding the interaction between cytomegalovirus and tuberculosis in children: The way forward.了解巨细胞病毒和结核病在儿童中的相互作用：前进的方向。
PLoS Pathog. 2021 Dec 9;17(12):e1010061. doi: 10.1371/journal.ppat.1010061. eCollection 2021 Dec.
10
Evasion of the Host Immune Response by Betaherpesviruses.β疱疹病毒对宿主免疫应答的逃避。
Int J Mol Sci. 2021 Jul 13;22(14):7503. doi: 10.3390/ijms22147503.
本文引用的文献
1
The Status of Vaccine Development Against the Human Cytomegalovirus.人类巨细胞病毒疫苗的研发现状。
J Infect Dis. 2020 Mar 5;221(Suppl 1):S113-S122. doi: 10.1093/infdis/jiz447.
2
Review of Mathematical Models of Vaccination for Preventing Congenital Cytomegalovirus Infection.预防先天性巨细胞病毒感染的疫苗接种数学模型综述。
J Infect Dis. 2020 Mar 5;221(Suppl 1):S86-S93. doi: 10.1093/infdis/jiz402.
3
Vaccine induction of antibodies and tissue-resident CD8+ T cells enhances protection against mucosal SHIV-infection in young macaques.疫苗诱导的抗体和组织驻留的 CD8+T 细胞增强了对幼年恒河猴黏膜 SHIV 感染的保护作用。
JCI Insight. 2019 Feb 21;4(4). doi: 10.1172/jci.insight.126047.
4
HCMV trimer- and pentamer-specific antibodies synergize for virus neutralization but do not correlate with congenital transmission.HCMV 三聚体和五聚体特异性抗体协同发挥病毒中和作用，但与先天传播无关。
Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3728-3733. doi: 10.1073/pnas.1814835116. Epub 2019 Feb 7.
5
Pathogen at the Gates: Human Cytomegalovirus Entry and Cell Tropism.病原体入侵：人巨细胞病毒进入和细胞嗜性。
Viruses. 2018 Dec 11;10(12):704. doi: 10.3390/v10120704.
6
Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response.新型三聚体人巨细胞病毒糖蛋白 B 引发高滴度中和抗体反应。
Vaccine. 2018 Sep 5;36(37):5580-5590. doi: 10.1016/j.vaccine.2018.07.056. Epub 2018 Aug 3.
7
There Is Always Another Way! Cytomegalovirus' Multifaceted Dissemination Schemes.总有另一种方法！巨细胞病毒的多方面传播策略。
Viruses. 2018 Jul 20;10(7):383. doi: 10.3390/v10070383.
8
Nonprimary Maternal Cytomegalovirus Infection After Viral Shedding in Infants.婴儿病毒脱落后排非原发性母体巨细胞病毒感染。
Pediatr Infect Dis J. 2018 Jul;37(7):627-631. doi: 10.1097/INF.0000000000001877.
9
HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions.巨细胞病毒糖蛋白 B 亚单位疫苗通过非中和抗体效应功能介导的功效。
Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):6267-6272. doi: 10.1073/pnas.1800177115. Epub 2018 Apr 30.
10
Vaccination against the human cytomegalovirus.人巨细胞病毒疫苗接种。
Vaccine. 2019 Nov 28;37(50):7437-7442. doi: 10.1016/j.vaccine.2018.02.089. Epub 2018 Apr 3.
Zotero 插件